Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
NEWS PRAN
Prana to commence Phase IIb trial on PBT2
- 525 Alzheimer's disease patients to be treated for 12 months -
Melbourne - 20 April 2010: Prana Biotechnology (NASDAQ:PRAN; ASX:PBT) today announced that it is finalising plans to commence a definitive Phase IIb trial of its lead Alzheimer's disease drug, PBT2, before the end of this year.
The Phase IIb trial will involve 525 patients with mild to moderate Alzheimer's disease. Treatment will be over a period of 12 months, with the key performance measure being cognition (including ADAS Cog* and Executive Function tests from the NTB*). The trial, a double blind placebo controlled study, will test the efficacy of 2 doses of PBT2 (250mg and 100mg). "We are excited by this protocol because we already know how patients benefited from a 250mg dose of PBT2 in just 12 weeks, so we are confident the benefit will be even stronger and more pronounced over a 12 month trial" said Mr. Kempler. "This trial is all about cognition and helping patients".
"Over recent years most drug companies have made late stage drug development decisions based on secondary biomarkers and imaging. Certainly, many have seen amyloid signals, but not necessarily robust cognition outcomes. PBT2 has shown both positive cognitive and biomarker changes, which is why we are so optimistic in the ability of PBT2 to really help sufferers of Alzheimer's disease".
The Company has prepared an explanation of its understanding of how PBT2 works in the brains of patients with Alzheimer's disease and in particular how PBT2 is uniquely different to other approaches for treating the disease. The explanation, in the form of a Mechanism of Action Position Statement will be available on the Prana website next week.
"The landscape has changed. Patients need and deserve a therapeutic solution based on strong science as well as clinical trials that translate the science into real benefits for patients. We believe that PBT2 will achieve this" concluded Mr. Kempler.
Discussions with potential sources of finance for the upcoming trial, both with investors and pharmaceutical partners, are progressing well and we will keep our shareholders updated.
* ADAS-Cog (Alzheimer's Disease Assessment Scale - cognitive subset) and NTB (Neuropsychological Test Battery) are tests given to Alzheimer's disease
patients to measure changes in memory and Executive Function.
http://www.pranabio.com/downloads/Media%20Releases/Prana%20to%20commence%20Phase%2011b%20trial%20on%20PBT2%20-%2020Apr10.pdf
NEWS PRAN
Prana to commence Phase IIb trial on PBT2
- 525 Alzheimer's disease patients to be treated for 12 months -
Melbourne - 20 April 2010: Prana Biotechnology (NASDAQ:PRAN; ASX:PBT) today announced that it is finalising plans to commence a definitive Phase IIb trial of its lead Alzheimer's disease drug, PBT2, before the end of this year.
The Phase IIb trial will involve 525 patients with mild to moderate Alzheimer's disease. Treatment will be over a period of 12 months, with the key performance measure being cognition (including ADAS Cog* and Executive Function tests from the NTB*). The trial, a double blind placebo controlled study, will test the efficacy of 2 doses of PBT2 (250mg and 100mg). "We are excited by this protocol because we already know how patients benefited from a 250mg dose of PBT2 in just 12 weeks, so we are confident the benefit will be even stronger and more pronounced over a 12 month trial" said Mr. Kempler. "This trial is all about cognition and helping patients".
"Over recent years most drug companies have made late stage drug development decisions based on secondary biomarkers and imaging. Certainly, many have seen amyloid signals, but not necessarily robust cognition outcomes. PBT2 has shown both positive cognitive and biomarker changes, which is why we are so optimistic in the ability of PBT2 to really help sufferers of Alzheimer's disease".
The Company has prepared an explanation of its understanding of how PBT2 works in the brains of patients with Alzheimer's disease and in particular how PBT2 is uniquely different to other approaches for treating the disease. The explanation, in the form of a Mechanism of Action Position Statement will be available on the Prana website next week.
"The landscape has changed. Patients need and deserve a therapeutic solution based on strong science as well as clinical trials that translate the science into real benefits for patients. We believe that PBT2 will achieve this" concluded Mr. Kempler.
Discussions with potential sources of finance for the upcoming trial, both with investors and pharmaceutical partners, are progressing well and we will keep our shareholders updated.
* ADAS-Cog (Alzheimer's Disease Assessment Scale - cognitive subset) and NTB (Neuropsychological Test Battery) are tests given to Alzheimer's disease
patients to measure changes in memory and Executive Function.
http://www.pranabio.com/downloads/Media%20Releases/Prana%20to%20commence%20Phase%2011b%20trial%20on%20PBT2%20-%2020Apr10.pdf
NEWS PRAN
Prana to commence Phase IIb trial on PBT2
- 525 Alzheimer's disease patients to be treated for 12 months -
Melbourne - 20 April 2010: Prana Biotechnology (NASDAQ:PRAN; ASX:PBT) today announced that it is finalising plans to commence a definitive Phase IIb trial of its lead Alzheimer's disease drug, PBT2, before the end of this year.
The Phase IIb trial will involve 525 patients with mild to moderate Alzheimer's disease. Treatment will be over a period of 12 months, with the key performance measure being cognition (including ADAS Cog* and Executive Function tests from the NTB*). The trial, a double blind placebo controlled study, will test the efficacy of 2 doses of PBT2 (250mg and 100mg). "We are excited by this protocol because we already know how patients benefited from a 250mg dose of PBT2 in just 12 weeks, so we are confident the benefit will be even stronger and more pronounced over a 12 month trial" said Mr. Kempler. "This trial is all about cognition and helping patients".
"Over recent years most drug companies have made late stage drug development decisions based on secondary biomarkers and imaging. Certainly, many have seen amyloid signals, but not necessarily robust cognition outcomes. PBT2 has shown both positive cognitive and biomarker changes, which is why we are so optimistic in the ability of PBT2 to really help sufferers of Alzheimer's disease".
The Company has prepared an explanation of its understanding of how PBT2 works in the brains of patients with Alzheimer's disease and in particular how PBT2 is uniquely different to other approaches for treating the disease. The explanation, in the form of a Mechanism of Action Position Statement will be available on the Prana website next week.
"The landscape has changed. Patients need and deserve a therapeutic solution based on strong science as well as clinical trials that translate the science into real benefits for patients. We believe that PBT2 will achieve this" concluded Mr. Kempler.
Discussions with potential sources of finance for the upcoming trial, both with investors and pharmaceutical partners, are progressing well and we will keep our shareholders updated.
* ADAS-Cog (Alzheimer's Disease Assessment Scale - cognitive subset) and NTB (Neuropsychological Test Battery) are tests given to Alzheimer's disease
patients to measure changes in memory and Executive Function.
http://www.pranabio.com/downloads/Media%20Releases/Prana%20to%20commence%20Phase%2011b%20trial%20on%20PBT2%20-%2020Apr10.pdf
PRAN NEWS!
Prana to commence Phase IIb trial on PBT2
- 525 Alzheimer's disease patients to be treated for 12 months -
Melbourne - 20 April 2010: Prana Biotechnology (NASDAQ:PRAN; ASX:PBT) today announced that it is finalising plans to commence a definitive Phase IIb trial of its lead Alzheimer's disease drug, PBT2, before the end of this year.
The Phase IIb trial will involve 525 patients with mild to moderate Alzheimer's disease. Treatment will be over a period of 12 months, with the key performance measure being cognition (including ADAS Cog* and Executive Function tests from the NTB*). The trial, a double blind placebo controlled study, will test the efficacy of 2 doses of PBT2 (250mg and 100mg). "We are excited by this protocol because we already know how patients benefited from a 250mg dose of PBT2 in just 12 weeks, so we are confident the benefit will be even stronger and more pronounced over a 12 month trial" said Mr. Kempler. "This trial is all about cognition and helping patients".
"Over recent years most drug companies have made late stage drug development decisions based on secondary biomarkers and imaging. Certainly, many have seen amyloid signals, but not necessarily robust cognition outcomes. PBT2 has shown both positive cognitive and biomarker changes, which is why we are so optimistic in the ability of PBT2 to really help sufferers of Alzheimer's disease".
The Company has prepared an explanation of its understanding of how PBT2 works in the brains of patients with Alzheimer's disease and in particular how PBT2 is uniquely different to other approaches for treating the disease. The explanation, in the form of a Mechanism of Action Position Statement will be available on the Prana website next week.
"The landscape has changed. Patients need and deserve a therapeutic solution based on strong science as well as clinical trials that translate the science into real benefits for patients. We believe that PBT2 will achieve this" concluded Mr. Kempler.
Discussions with potential sources of finance for the upcoming trial, both with investors and pharmaceutical
partners, are progressing well and we will keep our shareholders updated.
* ADAS-Cog (Alzheimer's Disease Assessment Scale - cognitive subset) and NTB (Neuropsychological Test Battery) are tests given to Alzheimer's disease patients to measure changes in memory and Executive
Function.
http://www.pranabio.com/downloads/Media%20Releases/Prana%20to%20commence%20Phase%2011b%20trial%20on%20PBT2%20-%2020Apr10.pdf
PRAN NEWS!
Prana to commence Phase IIb trial on PBT2
- 525 Alzheimer's disease patients to be treated for 12 months -
Melbourne - 20 April 2010: Prana Biotechnology (NASDAQ:PRAN; ASX:PBT) today announced that it is finalising plans to commence a definitive Phase IIb trial of its lead Alzheimer's disease drug, PBT2, before the end of this year.
The Phase IIb trial will involve 525 patients with mild to moderate Alzheimer's disease. Treatment will be over a period of 12 months, with the key performance measure being cognition (including ADAS Cog* and Executive Function tests from the NTB*). The trial, a double blind placebo controlled study, will test the efficacy of 2 doses of PBT2 (250mg and 100mg). "We are excited by this protocol because we already know how patients benefited from a 250mg dose of PBT2 in just 12 weeks, so we are confident the benefit will be even stronger and more pronounced over a 12 month trial" said Mr. Kempler. "This trial is all about cognition and helping patients".
"Over recent years most drug companies have made late stage drug development decisions based on secondary biomarkers and imaging. Certainly, many have seen amyloid signals, but not necessarily robust cognition outcomes. PBT2 has shown both positive cognitive and biomarker changes, which is why we are so optimistic in the ability of PBT2 to really help sufferers of Alzheimer's disease".
The Company has prepared an explanation of its understanding of how PBT2 works in the brains of patients with Alzheimer's disease and in particular how PBT2 is uniquely different to other approaches for treating the disease. The explanation, in the form of a Mechanism of Action Position Statement will be available on the Prana website next week.
"The landscape has changed. Patients need and deserve a therapeutic solution based on strong science as well as clinical trials that translate the science into real benefits for patients. We believe that PBT2 will achieve this" concluded Mr. Kempler.
Discussions with potential sources of finance for the upcoming trial, both with investors and pharmaceutical
partners, are progressing well and we will keep our shareholders updated.
* ADAS-Cog (Alzheimer's Disease Assessment Scale - cognitive subset) and NTB (Neuropsychological Test Battery) are tests given to Alzheimer's disease patients to measure changes in memory and Executive
Function.
http://www.pranabio.com/downloads/Media%20Releases/Prana%20to%20commence%20Phase%2011b%20trial%20on%20PBT2%20-%2020Apr10.pdf
PRAN NEWS!
Prana to commence Phase IIb trial on PBT2
- 525 Alzheimer's disease patients to be treated for 12 months -
Melbourne - 20 April 2010: Prana Biotechnology (NASDAQ:PRAN; ASX:PBT) today announced that it is finalising plans to commence a definitive Phase IIb trial of its lead Alzheimer's disease drug, PBT2, before the end of this year.
The Phase IIb trial will involve 525 patients with mild to moderate Alzheimer's disease. Treatment will be over a period of 12 months, with the key performance measure being cognition (including ADAS Cog* and Executive Function tests from the NTB*). The trial, a double blind placebo controlled study, will test the efficacy of 2 doses of PBT2 (250mg and 100mg). "We are excited by this protocol because we already know how patients benefited from a 250mg dose of PBT2 in just 12 weeks, so we are confident the benefit will be even stronger and more pronounced over a 12 month trial" said Mr. Kempler. "This trial is all about cognition and helping patients".
"Over recent years most drug companies have made late stage drug development decisions based on secondary biomarkers and imaging. Certainly, many have seen amyloid signals, but not necessarily robust cognition outcomes. PBT2 has shown both positive cognitive and biomarker changes, which is why we are so optimistic in the ability of PBT2 to really help sufferers of Alzheimer's disease".
The Company has prepared an explanation of its understanding of how PBT2 works in the brains of patients with Alzheimer's disease and in particular how PBT2 is uniquely different to other approaches for treating the disease. The explanation, in the form of a Mechanism of Action Position Statement will be available on the Prana website next week.
"The landscape has changed. Patients need and deserve a therapeutic solution based on strong science as well as clinical trials that translate the science into real benefits for patients. We believe that PBT2 will achieve this" concluded Mr. Kempler.
Discussions with potential sources of finance for the upcoming trial, both with investors and pharmaceutical partners, are progressing well and we will keep our shareholders updated.
* ADAS-Cog (Alzheimer's Disease Assessment Scale - cognitive subset) and NTB (Neuropsychological Test Battery) are tests given to Alzheimer's disease patients to measure changes in memory and Executive
Function.
http://www.pranabio.com/downloads/Media%20Releases/Prana%20to%20commence%20Phase%2011b%20trial%20on%20PBT2%20-%2020Apr10.pdf
NEWS
Prana to commence Phase IIb trial on PBT2
- 525 Alzheimer's disease patients to be treated for 12 months -
Melbourne - 20 April 2010: Prana Biotechnology (NASDAQ:PRAN; ASX:PBT) today announced that it is finalising plans to commence a definitive Phase IIb trial of its lead Alzheimer's disease drug, PBT2, before the end of this year.
The Phase IIb trial will involve 525 patients with mild to moderate Alzheimer's disease. Treatment will be over a period of 12 months, with the key performance measure being cognition (including ADAS Cog* and Executive Function tests from the NTB*). The trial, a double blind placebo controlled study, will test the efficacy of 2 doses of PBT2 (250mg and 100mg). "We are excited by this protocol because we already know how patients benefited from a 250mg dose of PBT2 in just 12 weeks, so we are confident the benefit will be even stronger and more pronounced over a 12 month trial" said Mr. Kempler. "This trial is all about cognition and helping patients".
"Over recent years most drug companies have made late stage drug development decisions based on secondary biomarkers and imaging. Certainly, many have seen amyloid signals, but not necessarily robust cognition outcomes. PBT2 has shown both positive cognitive and biomarker changes, which is why we are so optimistic in the ability of PBT2 to really help sufferers of Alzheimer's disease".
The Company has prepared an explanation of its understanding of how PBT2 works in the brains of patients with Alzheimer's disease and in particular how PBT2 is uniquely different to other approaches for treating the disease. The explanation, in the form of a Mechanism of Action Position Statement will be available on the Prana website next week.
"The landscape has changed. Patients need and deserve a therapeutic solution based on strong science as well as clinical trials that translate the science into real benefits for patients. We believe that PBT2 will achieve this" concluded Mr. Kempler.
Discussions with potential sources of finance for the upcoming trial, both with investors and pharmaceutical partners, are progressing well and we will keep our shareholders updated.
* ADAS-Cog (Alzheimer's Disease Assessment Scale - cognitive subset) and NTB (Neuropsychological Test Battery) are tests given to Alzheimer's disease patients to measure changes in memory and Executive Function.
http://www.pranabio.com/downloads/Media%20Releases/Prana%20to%20commence%20Phase%2011b%20trial%20on%20PBT2%20-%2020Apr10.pdf
IMPORTANT MUST READ>>>MCCI
1}SKTS REPORTS/confirmed that they owned 59%of mcci..co was reluctant to say but has confirmed.. and the pk reporting is in its final stage.guys this is a gold mine .a couple of penny is possible here .news could be out before the end of this month heck next 2 weeks.
skts trade in germany at 1.75
i can see many here are very frustrated but every doy has it day.these are the stocks that just explode outta nowhere ....ill be buying , at-least until sea-kinetics become fully reporting an release news .have a good day everyone patience is usually rewarded
IMPORTANT MUST READ>>>MCCI
1}SKTS REPORTS/confirmed that they owned 59%of mcci..co was reluctant to say but has confirmed.. and the pk reporting is in its final stage.guys this is a gold mine .a couple of penny is possible here .news could be out before the end of this month heck next 2 weeks.
skts trade in germany at 1.75
i can see many here are very frustrated but every doy has it day.these are the stocks that just explode outta nowhere ....ill be buying , at-least until sea-kinetics become fully reporting an release news .have a good day everyone patience is usually rewarded
i can see many here are very frustrated but every doy has it day.these are the stocks that just explode outta nowhere ....ill be buying , at-least until sea-kinetics become fully reporting an release news .have a good day everyone patience is usually rewarded
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=48901222
1]MCCI... MUST READ.... here the scoop OR DD for all looking to invest in MCCI..
the president of marketing concept intl.MCCI} has recently passed away .so am led to believe that the silent of the company aka lack of PR was due to the fact that the C.E.O. Mr mann was ill leading up to his death recently.
2}There has been changes in board members as stated on pinksheets.
we longs of mcci for month has been speculating that there was a merger in works. after many DD and many clues along the way
WE CAN SAY THAT WE FINALLY GOT IN CONTACT WITH THE C.E.O OF SEAKINETIC AND THE C.E.O HAS CONFIRMED VIA" PHONE CALL THAT THE MERGER WAS A SUCCESS ...YES THE MERGER DID HAPPENED HUGE NEWS FOR MCCI... AND FOR MANY REASONS AS STATED BELOW.
NOTE:SKTS is in the process of becoming fully PK reporting withing the next few weeks and a huge PR will follow stated by Mr. Jagtar (Jack) Dhaliwal – Executive Vice President, Chief Technology Officer, Director of seakinetics.
3}RECENT PR
The Company's President and CEO, Kenneth W Mann confirmed that the final agreement provides for an exchange of treasury stock from each Company as follows: Seakinetics, which currently trades on the Frankfurt Exchange at roughly 1.75 Euro per share, will deposit into the Company's trust account 160,000 restricted shares of its stock with a current market value of USD $328,000 in exchange for a 37.5% interest in Marketing Concepts International. Seakinetics will retain a further option for an additional 15% of treasury stock issued under rule 144 at a discount of 10% to market.
4}AS the PR stated the benifts of the merger are: mcci share price should rise dramatically, and with the company history of not having a R/S since 2004 we should have a share buy back which we all know rises a share price.
5}owners of {skts} and {mcci} history:
seakinetics trades in germay at $1.75
marketing concepts intcc. trades at .0002.
MCCI ceo: mr kenneth mann aka former ceo, and
SKTS ceo:James C Shelley, President, CEO & Director
were both on the board of directors for Americhip company.seems mr mann was the president of americhip during 2008 and shelly seems to be director of americhip international as well so they both worked together before and also were possible friends as well.
6}MCCI OFFICIAL UPDATES FROM TDAMERITRADE ASSOCIATES! unchanged ss: **The total shares outstanding for Marketing Concepts as of 1-25-2010 are 1,999,980,416 shares outstanding with 1,905,867,327 shares free trading and 94,113,089 restricted with 2,000,000,000 shares authorized.
We are confirming with the company if there is a change of officers.
Thank you,
Jason M. Bogutski-President
SIGNATURE STOCK TRANSFER, INC.
2632 Coachlight Court
Plano, Texas 75093
Tel 972 612 4120
Fax 972 612 4122
Email - signaturestocktransfer@msn.com
7}. Unlike traditional venture capital firms, MCCI will generate
revenue from net sales even if the client corporation is not
yet profitable. This means a greater return in a shorter period
of time with less risk.
B}. As a significant portion of the revenue earned will be distributed
directly to our shareholders; there will be much less risk.
C}. The shareholder income distribution will insure that there is an
inherent value to MCCI shares, and should serve to maintain a
stronger and more consistent share value.
D}. With the option to acquire 25% of the client corporation after
three years of sales activity, we can promise our shareholders
that the value of the acquisition will far exceed the investment
cost. The structure of the basic agreements between Marketing
Concepts and its clients will substantially reduce risks usually
Associated with this type of investment.
4}Seakinetics was established for the purpose of designing, developing, marketing and investing in innovative technologies and services in the renewable energy field. Seakinetics' mission is to be the best in finding solutions for renewable energy today and for the foreseeable future.
thank you guys for reading and we will be rewarded mcci looks very good and could take of at any time.http://investorshub.advfn.com/boards/read_msg.aspx?message_id=48706277
1]MCCI... MUST READ.... here the scoop OR DD for all looking to invest in MCCI..
the president of marketing concept intl.MCCI} has recently passed away .so am led to believe that the silent of the company aka lack of PR was due to the fact that the C.E.O. Mr mann was ill leading up to his death recently.
2}There has been changes in board members as stated on pinksheets.
we longs of mcci for month has been speculating that there was a merger in works. after many DD and many clues along the way
WE CAN SAY THAT WE FINALLY GOT IN CONTACT WITH THE C.E.O OF SEAKINETIC AND THE C.E.O HAS CONFIRMED VIA" PHONE CALL THAT THE MERGER WAS A SUCCESS ...YES THE MERGER DID HAPPENED HUGE NEWS FOR MCCI... AND FOR MANY REASONS AS STATED BELOW.
NOTE:SKTS is in the process of becoming fully PK reporting withing the next few weeks and a huge PR will follow stated by Mr. Jagtar (Jack) Dhaliwal – Executive Vice President, Chief Technology Officer, Director of seakinetics.
3}RECENT PR
The Company's President and CEO, Kenneth W Mann confirmed that the final agreement provides for an exchange of treasury stock from each Company as follows: Seakinetics, which currently trades on the Frankfurt Exchange at roughly 1.75 Euro per share, will deposit into the Company's trust account 160,000 restricted shares of its stock with a current market value of USD $328,000 in exchange for a 37.5% interest in Marketing Concepts International. Seakinetics will retain a further option for an additional 15% of treasury stock issued under rule 144 at a discount of 10% to market.
4}AS the PR stated the benifts of the merger are: mcci share price should rise dramatically, and with the company history of not having a R/S since 2004 we should have a share buy back which we all know rises a share price.
5}owners of {skts} and {mcci} history:
seakinetics trades in germay at $1.75
marketing concepts intcc. trades at .0002.
MCCI ceo: mr kenneth mann aka former ceo, and
SKTS ceo:James C Shelley, President, CEO & Director
were both on the board of directors for Americhip company.seems mr mann was the president of americhip during 2008 and shelly seems to be director of americhip international as well so they both worked together before and also were possible friends as well.
6}MCCI OFFICIAL UPDATES FROM TDAMERITRADE ASSOCIATES! unchanged ss: **The total shares outstanding for Marketing Concepts as of 1-25-2010 are 1,999,980,416 shares outstanding with 1,905,867,327 shares free trading and 94,113,089 restricted with 2,000,000,000 shares authorized.
We are confirming with the company if there is a change of officers.
Thank you,
Jason M. Bogutski-President
SIGNATURE STOCK TRANSFER, INC.
2632 Coachlight Court
Plano, Texas 75093
Tel 972 612 4120
Fax 972 612 4122
Email - signaturestocktransfer@msn.com
7}. Unlike traditional venture capital firms, MCCI will generate
revenue from net sales even if the client corporation is not
yet profitable. This means a greater return in a shorter period
of time with less risk.
B}. As a significant portion of the revenue earned will be distributed
directly to our shareholders; there will be much less risk.
C}. The shareholder income distribution will insure that there is an
inherent value to MCCI shares, and should serve to maintain a
stronger and more consistent share value.
D}. With the option to acquire 25% of the client corporation after
three years of sales activity, we can promise our shareholders
that the value of the acquisition will far exceed the investment
cost. The structure of the basic agreements between Marketing
Concepts and its clients will substantially reduce risks usually
Associated with this type of investment.
4}Seakinetics was established for the purpose of designing, developing, marketing and investing in innovative technologies and services in the renewable energy field. Seakinetics' mission is to be the best in finding solutions for renewable energy today and for the foreseeable future.
thank you guys for reading and we will be rewarded mcci looks very good and could take of at any time.http://investorshub.advfn.com/boards/read_msg.aspx?message_id=48706277
MCCI next IVOI!
thx man
can come any time news! radar
thank mr.lol
1]MCCI... MUST READ.... here the scoop OR DD for all looking to invest in MCCI..
the president of marketing concept intl.MCCI} has recently passed away .so am led to believe that the silent of the company aka lack of PR was due to the fact that the C.E.O. Mr mann was ill leading up to his death recently.
2}There has been changes in board members as stated on pinksheets.
we longs of mcci for month has been speculating that there was a merger in works. after many DD and many clues along the way
WE CAN SAY THAT WE FINALLY GOT IN CONTACT WITH THE C.E.O OF SEAKINETIC AND THE C.E.O HAS CONFIRMED VIA" PHONE CALL THAT THE MERGER WAS A SUCCESS ...YES THE MERGER DID HAPPENED HUGE NEWS FOR MCCI... AND FOR MANY REASONS AS STATED BELOW.
NOTE:SKTS is in the process of becoming fully PK reporting withing the next few weeks and a huge PR will follow stated by Mr. Jagtar (Jack) Dhaliwal – Executive Vice President, Chief Technology Officer, Director of seakinetics.
3}RECENT PR
The Company's President and CEO, Kenneth W Mann confirmed that the final agreement provides for an exchange of treasury stock from each Company as follows: Seakinetics, which currently trades on the Frankfurt Exchange at roughly 1.75 Euro per share, will deposit into the Company's trust account 160,000 restricted shares of its stock with a current market value of USD $328,000 in exchange for a 37.5% interest in Marketing Concepts International. Seakinetics will retain a further option for an additional 15% of treasury stock issued under rule 144 at a discount of 10% to market.
4}AS the PR stated the benifts of the merger are: mcci share price should rise dramatically, and with the company history of not having a R/S since 2004 we should have a share buy back which we all know rises a share price.
5}owners of {skts} and {mcci} history:
seakinetics trades in germay at $1.75
marketing concepts intcc. trades at .0002.
MCCI ceo: mr kenneth mann aka former ceo, and
SKTS ceo:James C Shelley, President, CEO & Director
were both on the board of directors for Americhip company.seems mr mann was the president of americhip during 2008 and shelly seems to be director of americhip international as well so they both worked together before and also were possible friends as well.
6}MCCI OFFICIAL UPDATES FROM TDAMERITRADE ASSOCIATES! unchanged ss: **The total shares outstanding for Marketing Concepts as of 1-25-2010 are 1,999,980,416 shares outstanding with 1,905,867,327 shares free trading and 94,113,089 restricted with 2,000,000,000 shares authorized.
We are confirming with the company if there is a change of officers.
Thank you,
Jason M. Bogutski-President
SIGNATURE STOCK TRANSFER, INC.
2632 Coachlight Court
Plano, Texas 75093
Tel 972 612 4120
Fax 972 612 4122
Email - signaturestocktransfer@msn.com
7}. Unlike traditional venture capital firms, MCCI will generate
revenue from net sales even if the client corporation is not
yet profitable. This means a greater return in a shorter period
of time with less risk.
B}. As a significant portion of the revenue earned will be distributed
directly to our shareholders; there will be much less risk.
C}. The shareholder income distribution will insure that there is an
inherent value to MCCI shares, and should serve to maintain a
stronger and more consistent share value.
D}. With the option to acquire 25% of the client corporation after
three years of sales activity, we can promise our shareholders
that the value of the acquisition will far exceed the investment
cost. The structure of the basic agreements between Marketing
Concepts and its clients will substantially reduce risks usually
Associated with this type of investment.
4}Seakinetics was established for the purpose of designing, developing, marketing and investing in innovative technologies and services in the renewable energy field. Seakinetics' mission is to be the best in finding solutions for renewable energy today and for the foreseeable future.
thank you guys for reading and we will be rewarded mcci looks very good and could take of at any time.http://investorshub.advfn.com/boards/read_msg.aspx?message_id=48706277
I have this week to buy just in case!
1]MCCI... MUST READ.... here the scoop OR DD for all looking to invest in MCCI..
the president of marketing concept intl.MCCI} has recently passed away .so am led to believe that the silent of the company aka lack of PR was due to the fact that the C.E.O. Mr mann was ill leading up to his death recently.
2}There has been changes in board members as stated on pinksheets.
we longs of mcci for month has been speculating that there was a merger in works. after many DD and many clues along the way
WE CAN SAY THAT WE FINALLY GOT IN CONTACT WITH THE C.E.O OF SEAKINETIC AND THE C.E.O HAS CONFIRMED VIA" PHONE CALL THAT THE MERGER WAS A SUCCESS ...YES THE MERGER DID HAPPENED HUGE NEWS FOR MCCI... AND FOR MANY REASONS AS STATED BELOW.
NOTE:SKTS is in the process of becoming fully PK reporting withing the next few weeks and a huge PR will follow stated by Mr. Jagtar (Jack) Dhaliwal – Executive Vice President, Chief Technology Officer, Director of seakinetics.
3}RECENT PR
The Company's President and CEO, Kenneth W Mann confirmed that the final agreement provides for an exchange of treasury stock from each Company as follows: Seakinetics, which currently trades on the Frankfurt Exchange at roughly 1.75 Euro per share, will deposit into the Company's trust account 160,000 restricted shares of its stock with a current market value of USD $328,000 in exchange for a 37.5% interest in Marketing Concepts International. Seakinetics will retain a further option for an additional 15% of treasury stock issued under rule 144 at a discount of 10% to market.
4}AS the PR stated the benifts of the merger are: mcci share price should rise dramatically, and with the company history of not having a R/S since 2004 we should have a share buy back which we all know rises a share price.
5}owners of {skts} and {mcci} history:
seakinetics trades in germay at $1.75
marketing concepts intcc. trades at .0002.
MCCI ceo: mr kenneth mann aka former ceo, and
SKTS ceo:James C Shelley, President, CEO & Director
were both on the board of directors for Americhip company.seems mr mann was the president of americhip during 2008 and shelly seems to be director of americhip international as well so they both worked together before and also were possible friends as well.
6}MCCI OFFICIAL UPDATES FROM TDAMERITRADE ASSOCIATES! unchanged ss: **The total shares outstanding for Marketing Concepts as of 1-25-2010 are 1,999,980,416 shares outstanding with 1,905,867,327 shares free trading and 94,113,089 restricted with 2,000,000,000 shares authorized.
We are confirming with the company if there is a change of officers.
Thank you,
Jason M. Bogutski-President
SIGNATURE STOCK TRANSFER, INC.
2632 Coachlight Court
Plano, Texas 75093
Tel 972 612 4120
Fax 972 612 4122
Email - signaturestocktransfer@msn.com
7}. Unlike traditional venture capital firms, MCCI will generate
revenue from net sales even if the client corporation is not
yet profitable. This means a greater return in a shorter period
of time with less risk.
B}. As a significant portion of the revenue earned will be distributed
directly to our shareholders; there will be much less risk.
C}. The shareholder income distribution will insure that there is an
inherent value to MCCI shares, and should serve to maintain a
stronger and more consistent share value.
D}. With the option to acquire 25% of the client corporation after
three years of sales activity, we can promise our shareholders
that the value of the acquisition will far exceed the investment
cost. The structure of the basic agreements between Marketing
Concepts and its clients will substantially reduce risks usually
Associated with this type of investment.
4}Seakinetics was established for the purpose of designing, developing, marketing and investing in innovative technologies and services in the renewable energy field. Seakinetics' mission is to be the best in finding solutions for renewable energy today and for the foreseeable future.
thank you guys for reading and we will be rewarded mcci looks very good and could take of at any time.http://investorshub.advfn.com/boards/read_msg.aspx?message_id=48706277
1]MCCI... MUST READ.... here the scoop OR DD for all looking to invest in MCCI..
the president of marketing concept intl.MCCI} has recently passed away .so am led to believe that the silent of the company aka lack of PR was due to the fact that the C.E.O. Mr mann was ill leading up to his death recently.
2}There has been changes in board members as stated on pinksheets.
we longs of mcci for month has been speculating that there was a merger in works. after many DD and many clues along the way
WE CAN SAY THAT WE FINALLY GOT IN CONTACT WITH THE C.E.O OF SEAKINETIC AND THE C.E.O HAS CONFIRMED VIA" PHONE CALL THAT THE MERGER WAS A SUCCESS ...YES THE MERGER DID HAPPENED HUGE NEWS FOR MCCI... AND FOR MANY REASONS AS STATED BELOW.
NOTE:SKTS is in the process of becoming fully PK reporting withing the next few weeks and a huge PR will follow stated by Mr. Jagtar (Jack) Dhaliwal – Executive Vice President, Chief Technology Officer, Director of seakinetics.
3}RECENT PR
The Company's President and CEO, Kenneth W Mann confirmed that the final agreement provides for an exchange of treasury stock from each Company as follows: Seakinetics, which currently trades on the Frankfurt Exchange at roughly 1.75 Euro per share, will deposit into the Company's trust account 160,000 restricted shares of its stock with a current market value of USD $328,000 in exchange for a 37.5% interest in Marketing Concepts International. Seakinetics will retain a further option for an additional 15% of treasury stock issued under rule 144 at a discount of 10% to market.
4}AS the PR stated the benifts of the merger are: mcci share price should rise dramatically, and with the company history of not having a R/S since 2004 we should have a share buy back which we all know rises a share price.
5}owners of {skts} and {mcci} history:
seakinetics trades in germay at $1.75
marketing concepts intcc. trades at .0002.
MCCI ceo: mr kenneth mann aka former ceo, and
SKTS ceo:James C Shelley, President, CEO & Director
were both on the board of directors for Americhip company.seems mr mann was the president of americhip during 2008 and shelly seems to be director of americhip international as well so they both worked together before and also were possible friends as well.
6}MCCI OFFICIAL UPDATES FROM TDAMERITRADE ASSOCIATES! unchanged ss: **The total shares outstanding for Marketing Concepts as of 1-25-2010 are 1,999,980,416 shares outstanding with 1,905,867,327 shares free trading and 94,113,089 restricted with 2,000,000,000 shares authorized.
We are confirming with the company if there is a change of officers.
Thank you,
Jason M. Bogutski-President
SIGNATURE STOCK TRANSFER, INC.
2632 Coachlight Court
Plano, Texas 75093
Tel 972 612 4120
Fax 972 612 4122
Email - signaturestocktransfer@msn.com
7}. Unlike traditional venture capital firms, MCCI will generate
revenue from net sales even if the client corporation is not
yet profitable. This means a greater return in a shorter period
of time with less risk.
B}. As a significant portion of the revenue earned will be distributed
directly to our shareholders; there will be much less risk.
C}. The shareholder income distribution will insure that there is an
inherent value to MCCI shares, and should serve to maintain a
stronger and more consistent share value.
D}. With the option to acquire 25% of the client corporation after
three years of sales activity, we can promise our shareholders
that the value of the acquisition will far exceed the investment
cost. The structure of the basic agreements between Marketing
Concepts and its clients will substantially reduce risks usually
Associated with this type of investment.
4}Seakinetics was established for the purpose of designing, developing, marketing and investing in innovative technologies and services in the renewable energy field. Seakinetics' mission is to be the best in finding solutions for renewable energy today and for the foreseeable future.
thank you guys for reading and we will be rewarded mcci looks very good and could take of at any time.http://investorshub.advfn.com/boards/read_msg.aspx?message_id=48706277
when should have been where is the link to?